TB Alternative Assets Ltd. Makes New Investment in BioNTech SE Sponsored ADR $BNTX

TB Alternative Assets Ltd. acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 8,700 shares of the company’s stock, valued at approximately $855,000. BioNTech makes up 0.2% of TB Alternative Assets Ltd.’s portfolio, making the stock its 26th biggest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of BNTX. Integrated Wealth Concepts LLC bought a new stake in BioNTech during the 2nd quarter worth approximately $39,000. Farther Finance Advisors LLC increased its holdings in BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after purchasing an additional 118 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after acquiring an additional 506 shares in the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after purchasing an additional 1,423 shares during the period. Finally, Quintet Private Bank Europe S.A. raised its stake in BioNTech by 232.8% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after buying an additional 1,341 shares during the period. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BNTX. UBS Group reiterated a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Argus assumed coverage on shares of BioNTech in a report on Thursday, October 8th. They set a “hold” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research note on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $125.44.

BioNTech Stock Performance

Shares of BNTX opened at $90.20 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The stock has a 50 day moving average price of $99.10 and a two-hundred day moving average price of $95.33. The firm has a market capitalization of $22.81 billion, a P/E ratio of -11.52 and a beta of 1.25. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The company had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same period last year, the company earned ($1.60) earnings per share. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. Equities analysts forecast that BioNTech SE Sponsored ADR will post -6.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other BioNTech news, CEO Ugur Sahin sold 36,209 shares of the firm’s stock in a transaction on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares in the company, valued at approximately $3,453,252.33. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 807,209 shares of company stock valued at $79,246,837. Corporate insiders own 19.20% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.